Genetics studies have found many genes associated with risk for atrial fibrillation (AF), a rapid rhythm in the upper chambers of the heart that can predispose to heart failure and stroke. The top DNA sites are near a gene that is involved with development of pulmonary veins (PVs), the veins leading from the lungs to the left atrium, which are the main target of AF ablation, a treatment for AF. However, how these genes lead to AF remain undefined, but some studies have reported higher risk of failing catheter ablation procedures for AF with certain gene variants. With the expanding development of artificial intelligence methods that can be used to analyze images like cardiac magnetic resonance imaging studies, we aim to find what is different in the atria and PVs that predispose to AF risk and AF ablation success. We believe that these differences may arise from the strong AF genetic risk sites related to formation of the PVs. Ablation for AF has limited success. Finding better targets that improve AF therapies through these imaging and genetic methods directly supports the AHA mission to build healthier lives free of AF and potentially stroke risk. Our studies will work for healthy equity for all Americans, hopefully improving outcomes across all genetic backgrounds.
|Effective start/end date||7/1/20 → 6/30/22|
- Cleveland Clinic Foundation (AGMT 5/11/21//20SCG35490449)
- American Heart Association (AGMT 5/11/21//20SCG35490449)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.